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 A STUDY OF SERUM MAGNESIUM LEVELS AT PRESENTATION OF 
ACUTE MYOCARDIAL INFARCTION 
Abstract 
Background: According to many studies, acute myocardial infarction is 
associated with an increased incidence of hypomagnesemia.This may contribute 
to increase in the incidence of arrhythmias and complications, during the early 
period of acute MI. 
Aims: To find out the prevalence of hypomagnesemia in the study population, 
and also to compare the mean magnesium levels in the study population and the 
control population. We will also see if the incidence of complications are higher 
in the hypomagnesemic patients 
Materials and methods: 70 patients who presented with acute MI in 
Tirunelveli Medical College hospital ICCU, who did not fit into the exclusion 
criteria were taken as the study population. The control group had 30 
participants. The serum magnesium levels were measured using the colorimetric 
method. 
Results: Out of the 70 cases only one patient had hypomagnesemia.(1.43%). 
This was not significant He did not develop any complications. The mean  
 
 magnesium levels of the study group (2.01mg/dl)was however significantly 
lower than that of the control group(2.18mg/dl).( (p value<0.01).   
Conclusion: In this study, the prevalence of hypomagnesemia in MI patients 
was not significant. However the mean serum magnesium level of the study 
group was significantly lower than that of the control group. This study thus 
differs from the other similar studies conducted in the western population. The 
reason could be attributed to the high concentration of magnesium ions in the 
local ground water. Further studies must be done in Indian population to see if 
these results are reproducible or not. 
Key words: Acute myocardial infarction, serum magnesium levels, 
hypomagnesemia, arrhythmias. 
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Introduction 
 Cardiovascular disease is still the most common cause of mortality and 
morbidity throughout the developing world. As we progress along the twenty first 
century, numerous technological innovations and breakthroughs has made our lives 
more and more easy. We are gradually beginning to realize some of the 
undesirable effects these events are having upon us, specifically regarding human 
health. 
 We as a species have existed on this planet for around 100,000 to 200,000 
years according the evidence suggested by mitochondrial DNA mutation studies. 
Human beings have evolved primarily as hunter gatherers. Our bodies and 
metabolism are genetically built in a specific way which made us adaptable to the 
tough environment that existed in the Palaeolithic age or Stone Age. In those 
conditions, food availability was relatively low and there were frequent episodes of 
famine. This is to say that the human body was designed to survive these episodes 
by storing excess energy in the form of fat deposits, during the times in which food 
was relatively abundant.  The breakthrough in agriculture came only around ten 
thousand years before. So for the huge majority of time in human history, we have 
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lived in times of shortage of food, rather than abundance of food.  So our genetic 
condition has made us adaptable to food scarcity and physical activity, but is not 
well adapted to deal with over-nutrition and a sedentary lifestyle. 
  
 We have virtually eliminated physical activity or exercise from our lives. 
Physical inactivity is the most important cause of the modern lifestyle disease 
leading to cardiovascular mortality. Adding to this there is the problem of over-
nutrition, especially of unhealthy food substances rich in saturated and trans-fatty 
acids, refined simple carbohydrates.  
 Increased work hours and academic competition, smaller nuclear families, 
noise pollution and all have greatly increased the stress levels, despite the 
conveniences offered by modern life. This transforms into organic diseases like 
hypertension, anxiety disorders and associated diseases which contribute to 
cardiovascular disease burden. 
 Coronary heart disease is the primary cause of cardiovascular mortality. 
Acute myocardial Infarction is the acute manifestation of coronary heart disease. 
Modern medicine has made numerous advances in managing the disease, 
including, fibrinolytic therapy, catheter based intervention, anti-platelet drugs, lipid 
lowering drugs, etc. Even with the best medical care, the in-hospital mortality of 
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acute myocardial infarctions stands at 2.5% to 5%. Considering the fact that acute 
MI is very common, the total number of lives lost is massive.  
 There is constant research not only to broaden our understanding of the 
established risk factors that affect the prognosis of acute myocardial infarction, but 
also to discover new prognostic indicators or risk factors. Many such factors such 
as C - reactive protein levels, blood uric acid levels, blood magnesium levels have 
been in the spotlight. 
 Magnesium is a very important element that plays innumerable roles in the 
proper functioning of the human body. It is a cofactor in many important enzymes 
involved in the metabolic functions of the body. It also has electrophysiological 
properties that affect ion transport and electrical transmission across cells, 
especially neurons and cardiac myocytes.   
 Magnesium is also used therapeutically in the treatment of seizures in 
eclampsia and in the treatment of Torsade des pointes which is a kind of 
ventricular tachycardia. It also has many adjuvant roles in similar disease 
conditions. 
 It is only reasonable to search for the importance of the role of magnesium 
in the pathophysiology and prognosis in acute myocardial infarction which can be 
arguably stated as one of the most dangerous of all the medical emergencies. 
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 This thesis titled “A study of serum Magnesium levels at presentation of 
acute myocardial infarction” is a humble attempt at searching for the presence of 
any significant change in blood magnesium levels of acute MI patients who present 
at Tirunelveli Medical College Hospital for its management. Previous studies have 
leaned towards the presence of reduced magnesium levels in acute myocardial 
infarction patients. Some studies have also associated a poorer prognosis in such 
patients. The prophylactic use of magnesium in acute MI patients is an even more 
controversial topic. This study intends to see if the results obtained in the study 
population are similar to the previous studies or not.  
 The following pages start with elaborating the aims and objectives of the 
study followed by a brief review of the existing literature regarding cardiovascular 
disease, myocardial infarction, and the role of magnesium in the human body, 
especially the cardiovascular system. Then there is a discussion of the methods and 
materials used for the study before we dwell into the observations and results. 
There will be a detailed discussion of the findings followed by a summary. Finally 
we reach the conclusion of the study. 
- Thank You. 
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Aims and Objectives 
 
 
1. To estimate the prevalence of hypomagnesemia in patients who present 
with acute myocardial infarction and to determine its significance. 
 
2. To find out if the hypomagnesemic patients are at a higher risk of 
ventricular arrhythmias or other complications. 
 
 
 
3. To compare the mean magnesium levels between the cases and the 
control group and find out if the difference, if any is statistically 
significant.  
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Global burden of Cardiovascular Disease 
 During the last ten years, cardiovascular disease has become the single 
biggest cause of death all over the world. In 2004, cardiovascular disease was 
responsible for an estimated 17 million deaths all over the world. It accounted for 
thirty per cent of deaths of that year. In 2004, it was the cause for 151 million 
disability adjusted life years (DALY) lost. It accounted to around 14 per cent 
DALYs lost during that year. (1).This pattern is seen in high income countries, 
middle income countries and low income countries regardless. The rates of 
cardiovascular disease are increasing. It is not only increasing, but also 
accelerating. 
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 Shifting of the burden 
 Cardiovascular disease is the leading cause of deaths in all the developing 
regions. The exception is sub-Saharan Africa. Even in sub Saharan Africa, it is the 
leading cause of deaths in individuals more than 45 years of age. This busts the 
myth that cardiovascular disease is a disease of affluent societies. Low and middle 
income countries are also bearing the burden. In fact more and more burden is 
shifting to the middle and low income countries. Between the years 1900 to2001, 
the deaths caused by cardiovascular disease in low and middle income countries 
sincreased from 26% to 28%. 
 
Current Worldwide Distribution of Cardiovascular Disease  
High-Income Countries 
940 million people currently inhabit the high income countries. This comes 
to around fifteen per cent of the world population. They consist of the United 
States of America, Canada, Australia, New Zealand, Japan, and many countries of 
the European Union.  
Here, there is overall increase in cardiovascular disease burden. The good 
news is that the age adjusted death rates for cardiovascular diseases are decreasing. 
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This is due to both primary and secondary prevention. The average age of death 
from CVD continues to increase. 
Low and middle- Income countries. 
 There are six regions that make up the low and middle-income countries. 
There is considerable variability in the distribution of cardiovascular disease 
between these regions. Here the prevalence of cardiovascular disease is increasing. 
The important thing to consider is that the age adjusted mortality is increasing. 
That means that coronary heart disease affects a younger population. 
These people constitute the workforce and thus it further hinders economic 
development in these countries. The lower socioeconomic strata are more 
vulnerable as they are least likely to apply health practices and to avail advanced 
treatments. 
South Asia Including India   
 It is one of the most densely populated regions. It contains 20% of the world 
population. This accounts to around 1.4 billion residents. India is the largest 
country in this region. It is the home to more than seventy five per cent of the 
regions inhabitants. 
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 Cardiovascular diseases accounted twenty five per cent of all the deaths in 
the region. Communicable diseases lead to 43% of all the deaths in this region, by 
comparison. (2) 
 The deaths from coronary heart disease in India is increasing.. Coronary 
heart disease rose from 1.17 million to 1.59 million over the previous decade. 
In India alone, 31.8 million people are lining with coronary heart disease.(27) This 
is a tenfold increase, when compared  the condition that existed 40 years ago. 
Women are more likely to develop cardiovascular disease in India.(39).  A new 
study found out that the prevalence in men was 6% and the prevalence in women 
was 9%. 
 Here there is an increased use of tobacco products among the people os 
lower socioeconomic status, leading to a higher burden of cardiovascular disease in 
them. In India, 52% of deaths due to cardiovascular disease occur in individuals 
below 70 years of age. This is a considerable burden on working age citizens.  
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Risk Factors 
Hypertension 
 Elevated Systemic blood pressure is an indicator of the transition in 
epidemiology. As the population becomes more and more industrialized, the mean 
blood pressure of the population increases. This is also true when the people move 
from rural to urban settings. There is a high rate of undetected and untreated 
hypertension in the developing countries. This is a major concern. This is true 
especially in Asia, this maybe the cause for high prevalence of haemorrhagic 
stroke.  
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Worldwide, around 62% of strokes and 49% of coronary heart disease are 
undoubtedly attributable to a sub-optimal blood pressure, i.e. more than 115 mm 
Hg. This accounts for more than 7 million deaths annually. 
Tobacco 
Tobacco use is the most preventable cause of death in the entire world.  Over 
1.3 billion people worldwide are consumers of tobacco. More than 1 billion people 
smoke. The others use oral tobacco or nasal tobacco. More than 80% of tobacco 
use occurs in low and middle income countries. If the current trend of tobacco use 
continues, there will be more than 1 billion deaths in the world during the twenty 
first century. Smoking related CHD deaths totaled 360,000 in 2000. There were 
200,000 cerebrovascular deaths due to smoking on the same year. (3) 
Second hand smoke also is now well established as a significant cause of 
coronary heart disease. There is a 1.3 fold increased risk of coronary heart disease 
following second hand smoking. 
Lipids 
Worldwide, increased levels of blood cholesterol, cause around 56 per cent 
of ischemic heart disease and 18 eighteen per cent of strokes. This amounts to 4.4 
million deaths in one year. Unfortunately the data on cholesterol levels is very 
limited in most of the developing countries. In high-income countries, the mean 
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level of cholesterol is gradually falling as a result of widespread use of 
medications. In low and middle income countries there is wide variation in 
cholesterol levels. 
As countries experience movement through the epidemiological transit, the 
mean population blood cholesterol levels typically increase. There is a very clear 
role played by the changes accompanying urbanization. This is evidenced by the 
fact that, the blood cholesterol levels are higher in urban residents than in rural 
residents. This change is largely a result of increased consumption of dietary fats, 
mainly from animal products and processed vegetable oils, and from decreased 
physical activity.  
Physical Inactivity 
 In high income countries, the widely spread prevalence of physical 
inactivity puts the population at a very high risk for cardiovascular consequences. 
In a poll conducted in 2007 found that a vast majority of adults are not following 
the recommended amount of exercise given in health guidelines. Current heath 
guidelines call for vigorous exercise for twenty minutes, 3 times a week. Or 
moderate exercise for at least 30 minutes, 5 or more days a week. 
 There is a shift from physically demanding agriculture based work 
and manual labour to a largely sedentary service industry. Office based work is 
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also increasing in the population of the developing world. There is also a change 
from physically demanding transportation to mechanized transportation. 
Diabetes  
Throughout the world, approximately One Eighty million people are 
affected by diabetes mellitus. The worrying fact is that this number is expected to 
double by the year 2030. Of the people with diabetes, around ninety per cent have 
type 2 diabetes. Eighty per cent of them live in low and middle income countries. 
In the developing countries, the age group of diabetics ranges from 45 to 64. In 
developed countries, the most affected individuals are more than 65 years of age.  
One interesting trend is that, Asian countries are more burdened with 
diabetes, when compared with Europe and Central Asia or Latin America and the 
Caribbean regions. India and China have the largest number of diabetic patients. 32 
million and 21 million respectively.(4 )Asian population have a greater tendency 
towards visceral obesity. This may be responsible for this peculiar finding. 
Obesity 
Obesity is increasing throughout the entire world, especially in the 
developing countries. The trajectory is also steeper than those seen in developed 
countries.  According to WHO, there are approximately 1.1 billion overweight 
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adults in the world. Another study claims that 23% of adults older than 20 years 
are overweight. 10% of them are obese (BMI>30).  
 Obesity is not only a problem in high income individuals. The poor 
are relatively more at risk for obesity as a developing country’s GDP moves closer 
to the middle income range. Women are more affected than men in these 
developing countries. This is based on data from 36 developing countries.    
One in ten children is currently estimated to be overweight. The number of 
overweight children is increasing in many countries like China, brazil, India, 
Mexico.  
In developing countries, even if the mean cholesterol levels are falling the 
mean BMI is increasing at an alarming rate. 
Diet 
There is an increase in the consumption of processed foods, people consume 
larger portions of food, the regularly consume sugary drinks. There is an increase 
in consumption of fats and simple carbohydrates, but there is a decrease in 
consumption of plant based foods. Saturated fatty acid intake is increased. 
Hydrogenated vegetable oils are also increasingly consumed. They contain 
atherogenic trans-fatty acids. High intake of trans-fatty acids may lead to 
abdominal obesity. 
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Another factor is the introduction of soft drinks and other high-sugar 
beverages. They are associated with weight gain and increase risk for type 2 
diabetes mellitus. They are an independent risk factor for coronary heart disease. 
(5) 
Aging Population 
As primary health care is improved and infectious diseases are controlled,  
more and more individuals live longer to reach old age. Proportion of people aged 
over 65 is more than one fifth in many developed countries. Elderly individuals are 
naturally more at risk for cardiovascular disease and more prone to suffer 
morbidity and mortality from the disease. 
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Ischemic Heart disease     
 
 Patients who are suffering from ischemic heart disease can be classified into 
two broad groups. One consists of patients with chronic coronary artery disease 
(CAD). They most commonly present with stable angina. 
 The second group is composed of patients with Acute Coronary syndromes 
(ACS). This group consists of a collection of syndromes consisting of: 
1. Acute myocardial infarction with ST- segment elevation 
2. Non St-segment elevation Myocardial Infarction. 
3. Unstable Angina. 
Unstable angina and non ST-segment elevation myocardial infarction are usually 
grouped together as they share similar treatment. 
 Incidence of ST-elevation myocardial infarction is less than that of unstable 
angina/non ST elevation MI. The relative incidence of NSTEMI/UA compared to 
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ST elevation MI appears to be increasing. More than one third of patients with 
unstable angina/non ST elevation MI are women. However less than one-fourth of 
patients with ST elevation Myocardial infarction are women. 
The most important difference between the two groups is regarding the need for 
fibrinolysis.                                                  
 
Definitions 
Stable angina pectoris is characterised by chest or arm discomfort that may not be 
always described as pain but is reproducibly associated with physical exertion 
and/or stress and is relieved within five to ten minutes by rest and/or sublingual 
administration of nitroglycerin. 
Unstable angina can be defined as angina pectoris or equivalent ischemic 
discomfort so that it also consists of at least one of the three features: 
1. It occurs during rest or with minimal physical exertion, and usually lasting 
for more than 10 minutes. 
2. It is severe and is of new onset. (mostly within the prior 4-6 weeks) 
3. It occurs with a crescendo pattern. It means that the angina is more severe, 
prolonged or more frequent than previously. 
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Non ST-segment elevation Myocardial infarction is diagnosed if a patient has 
the clinical features of unstable angina develops evidence of necrosis of 
myocardial tissue, as evidenced by elevated cardiac biomarkers. 
In both unstable angina and NSTEMI the pathology includes an unstable plaque, 
causing sub-total occlusion of the coronary arteries. Here fibrinolysis is of limited 
benefit or it may even be harmful. The fibrinolytic lyses the outer fibrin layer to 
expose the thrombogenic core of the unstable plaque, resulting in further 
enlargement of the clot. 
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ST- elevation myocardial infarction 
Myocardial infarction is almost always because of the formation of a 
thrombus at the site of erosion or rupture of an atheromatous plaque in a coronary 
artery. If the thrombus formed completely occludes the vascular lumen, ST 
elevation myocardial infarction is the result. 
The process of infarction progresses over a period of several hours and 
therefore most of the patients present when it is still possible to salvage 
myocardium and improve the outcome. 
 
Clinical features 
Pain is the cardinal symptom of myocardial infarction. Pain occurs at the 
same site as that of angina pectoris but it persists even during rest, is more severe 
and is more severe and lasts longer. The pain is described as tightness, heaviness or 
constriction in the chest. (6). 
There may be symptoms of sympathetic over activity associated with the 
pain. Breathlessness may be present along with the pain but sometimes it may be 
the only symptom. Pain may also be absent in diabetic patients or old patients.  
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Syncope or even sudden death from ventricular fibrillation or arrhythmias 
may occur immediately. Most of the deaths occur during the first 24 hours. Of 
these deaths majority of them occur in the first hour. 
Diagnosis 
 
 The electrocardiogram is the cornerstone of diagnosing STEMI (2). 
There is ST segment elevation in two or more contiguous leads, during the 
early hours of the disease. Soon it is followed by loss of the R wave over some 
hours.  T wave inversion occurs within a few days and over some days to weeks, a 
well-established Q wave is formed. 
Patients with typical symptoms of Acute myocardial infarction with the 
characteristic findings on ECG are diagnosed as ST- elevation MI and are 
candidates for fibrinolysis, after considering the time duration after the onset of 
symptoms, with the absence of contraindications.(7) 
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Biomarkers 
 The biomarkers most employed for diagnosis are Creatine Kinase – 
cardiospecific isoform (CK-MB), and other cardiospecific proteins Troponin-T and 
troponin-I. CK-MB starts to rise at six hours, peaks at 12 hours and falls to normal 
within three days. The cardiac troponins are elevated after 6 hours and remain 
elevated up to two weeks.(6).They are most important in the diagnosis of Non ST 
elevation Myocardial infarction. They are also important in assessing the 
progression of STEMI also. 
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Chest X ray may reveal pulmonary oedema not detectable by clinical 
examination. Echocardiogram may detect cardiac rupture, mitral regurgitation, 
ventricular septal rupture, pericardial effusion, mural thrombus. 
 
Management 
Immediate measures:  
The patient must be shifted to a coronary care unit with defibrillation 
facilities. I.V access is obtained immediately. Aspirin 300 mg is given 
immediately, along with 40-80 mg of atorvastatin. Intravenous analgesia using 
opiates is of very high importance. 
Reperfusion therapy:  
Reperfusion can be attempted using either fibrinolytic therapy or primary 
percutaneous intervention- primary PCI. 
Fibrinolysis: This is cheaper and more readily available than percutaneous 
intervention. Maximum effectiveness is achieved if it is performed within one 
hour. Benefit is still high if it is performed within 6 hours. Some benefit still 
remains if it is done within 12 hours. The risks outweigh the benefits after 12 hours 
have passed. 
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Primary PCI: When compared to fibrinolytic therapy, it is associated with a 
fifty percent greater reduction in risk of death and recurrence of myocardial 
infarction. (6). However it is not widely available. It may be attempted if 
fibrinolytic therapy has failed, especially in the setting of pump failure leading to 
pulmonary edema and/ or cardiogenic shock. 
Maintaining Patency of Vessel wall: Anti-platelet therapy: Daily oral 
administration of aspirin(75-300 mg) improves survival(1). There is a thirty per 
cent reduction in mortality. Clopidogrel 75 mg may be added as an antiplatelet as it 
further increases survival rates. 
Statins: Atorvastatin 20-40 mg daily not only acts as a lipid lowering drug, 
but also has a pleomorphic effect whereby it reduces the pro-inflammatory state 
and improves survival. 
Anticoagulants: Heparin when administered in addition to antiplatelets 
prevents reinfarction after fibrinolysis. It also reduces the risk of thromboembolic 
complications. 
Adjunctive Therapy:  
Nitrates: They are useful in relieving pain and for treatment of Left 
ventricular failure. 
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Beta blockers: Intravenous beta blockers are useful in reducing pain and in 
preventing arrhythmias, during the first 12 hours. They also improve short term 
mortality.(8) 
ACE inhibitors: They are useful in their action against left ventricular 
remodelling that may occur in the aftermath of an acute myocardial infarction. 
Complications: 
Arrhythmias:  
Ventricular fibrillation: This occurs in 5-10% of those who reach the 
hospital. Quick defibrillation will usually restore sinus rhythm. 
 
Atrial fibrillation: This is transient and may not require treatment. However 
if it is sever enough to cause circulatory collapse, cardioversion by synchronised 
DC shock must be given. 
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Sinus Bradycardia: Does not require treatment. Except in cases of 
hypotension where atropine may be administered. 
Atrioventricular Block: Usually temporary. May respond to atropine. If there 
is hypotension or second/third degree block, a temporary pacemaker should be 
considered. (8) 
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Ischemia: 
Post infarct angina occurs in upto 50% of patients. They should be managed 
similar to patients with unstable angina. 
Acute Circulatory failure: 
This reflects extensive myocardial damage. This usually indicates a poor 
prognosis. 
Pericarditis: Most common on the second and third day. NSAIDs and 
steroids are to be avoided as they increase the risk of wall rupture. Opioids are 
preferred. Dressler’s syndrome (fever, pericarditis) occur after a few weeks of the 
infarct. It Can be treated with NSAIDs. 
Papillary muscle damage: May cause acute MR and pulmonary edema. 
Surgical intervention may be needed in severe cases.(7) 
IV septum rupture: It is a rare complication. Without prompt surgery, the 
condition is usually fatal. 
Rupture of ventricle with cardiac tamponade: Usually fatal. Mild cases can 
be saved by early surgery.  
Ventricular remodelling: The infarct thins out and becomes inefficient in 
pumping. The left ventricle enlarges over a few months to years. This is called 
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remodelling. This progressively reduces the cardiac function. ACE inhibitor 
therapy reduces this phenomenon. 
Ventricular aneurism: It occurs in ten per cent of patients. It may lead to 
heart failure, ventricular arrhythmias, mural thrombus and systemic embolism. It 
causes a persistent ST elevation in the ECG. Surgery for removing the aneurism 
carries a very high mortality. So it must be undertaken only when absolutely 
necessary. 
Reperfusion injury 
 Even though reperfusion of the critically ischemic myocardial tissue is 
beneficial as it salvages the still viable myocardium, this may come at a cost of a 
process called as reperfusion injury. (9) There are many types of reperfusion 
injury. 
1. Lethal reperfusion injury: This is the reperfusion induced death of cells 
that were still viable at the time of restoration of coronary flow. 
2. Vascular reperfusion injury: this is the progressive damage to the 
microvasculature. There is an expanding area of no reflow and loss of 
coronary vasodilatory property. 
3. Stunned myocardium: Salvaged myocardium may display a prolonged 
period of contractile dysfunction, even after restoration of blood flow. 
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4. Reperfusion arrhythmias: there may be bursts of ventricular tachycardia 
and occasionally, ventricular fibrillation.  
Reperfusion increases the cell swelling that occurs with ischemia. There may 
be a creation of a haemorrhagic infarct. 
 Fibrinolytic therapy appears more likely to produce haemorrhage into 
the infarct than catheter based reperfusion. However the haemorrhage does 
not extend beyond the area of myocardial necrosis. So there is no infarct 
extension. 
Reperfusion arrhythmias: There may be a transient sinus bradycardia in 
patients with inferior wall infarction.  This is mostly associated with some 
amount of hypotension. (10) 
 Other common reperfusion arrhythmias are premature ventricular 
contractions, accelerated idioventricular rhythm, and non-sustained 
ventricular tachycardia. 
When reperfusion arrhythmias are present, they may actually indicate a 
successful restoration of coronary flow. Reperfusion arrhythmias have a 
high sensitivity for detecting successful reperfusion. This is especially 
important, considering the fact that clinical features are poor markers of 
myocardial reperfusion.  
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The arrhythmias show a temporal clustering during the time of 
restoration of coronary blood flow with successful fibrinolytic therapy, the 
overall incidence of such arrhythmias seems to be similar in patients who do 
not receive fibrinolytic agent. The brief electrical instability that occurs 
during reperfusion is generally innocuous and can be thought of as not life 
threatening. Considering the above factors, one may conclude that no 
prophylactic antiarrhythmic therapy is essential when fibrinolytics are 
prescribed. 
Magnesium in the human body 
Tissue Distribution  
The Entire human body consists of 760 milligrams of magnesium during 
birth. When one reaches five months of age, it will contain 5 grams of magnesium. 
When adulthood is attained, the entire body would contain up to 25 grams of 
magnesium. 
When we consider about the distribution of magnesium inside the body, we 
find that, thirty to forty per cent is confined inside the human musculature, the 
entire soft tissue mass, one per cent is found inside the extracellular fluid 
compartment of the body. The remaining fifty to sixty per cent is found inside the 
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skeletal system, where it is chemically combined with calcium salts in the form of 
hydroxy-apetite. Magnesium is calculated to be one per cent by weight of bone 
ash.(11,12) 
Functions 
The magnesium that is present inside the soft tissues has many important 
functions. It is a co-factor for many enzymes and proteins involved in metabolism 
of nutrients to release energy. It is also needed in enzymes for synthesis of 
proteins, synthesis of DNA, creation of RNA. It is indispensable, for maintaining 
the electrical potential across a cell, which is responsible for the creation of resting 
membrane potential, especially in cells like the neuron, the myocytes, and smooth 
muscles and such.  
Between fifty and sixty per cent of magnesium inside the human body is 
inside the skeletal system. It forms an important constituent of hydroxyl 
apetite(calcium phosphate), which is a mineral component. The important point is 
that, initially a significant amount of this magnesium can easily be exchanged with 
the serum. Thus bone stores are a relatively easy access site for serum magnesium, 
during times of deficiency. As the age advances, this process becomes less and less 
efficient. So the exchangeable fraction declines very significantly with increasing 
age(13). 
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Magnesium levels influence the potassium influx and efflux across the body 
compartments. It is also involved in the metabolism of calcium ions.(14,15). The 
depletion of magnesium reduces significantly, both intracellular and extracellular 
levels of potassium. It magnifies the effects of a low potassium diet. The reduction 
in muscle potassium levels is marked as magnesium deficiency develops. The 
replenishment of potassium is near to impossible unless the magnesium levels are 
restored to normal. 
There is development of low calcium levels in the plasma as the magnesium 
levels begin to drop. The exact reason for this phenomenon is unclear. Possible 
explanations include the inhibition of parathyroid hormone, secretion, directly or 
indirectly. A more probable explanation would be the reduction of the bone 
sensitivity to the action of parathyroid hormone. So in effect, there is reduction or 
restriction of removing calcium from the bone stores towards the serum. 
One important finding is that, when the diets of patients who suffered from 
gluten sensitive enteropathy were fortified with magnesium, many physiological 
events took place. There was significant increase in the bone mineral density of the 
femur. There was also increase in the levels of intracellular magnesium inside the 
erythrocytes.(16)  
Dietary sources 
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Deficiency of magnesium in the normal diet is usually not very severe. So, 
dietary deficiency itself does not usually cause pathological changes of significant 
severity.  Magnesium is distributed broadly in foods of plant and animal sources. 
Geological, chemical, and environmental variables are usually of little importance 
so as to have a major influence on the magnesium content inside common foods.  
Most legume seeds, green leafy vegetables, peas, nuts, and beans are rich in 
their magnesium content. Other sources include Shellfish, soya flour, many spices, 
molluscs and seafood. They usually contain more than 500mg/kilogram 
magnesium content. Even though, most of cereal grains that are unrefined, are 
sources with a reasonable magnesium content, many fully refined flours, tubers, 
roots are poor in magnesium content. Magnesium content is also very low in 
Fruits, fungi, most of the oils and fats. The foods that have very low magnesium 
content are Corn flour, cassava or tapioca, polished rice flour, sago flour, etc. 
Around fifty to ninety per cent of magnesium from mothers milk is absorbed 
by the infant. This can be considered as a very effective absorption mechanism. 
When studies on adult population were conducted, the results varied considerably. 
There seems to be a homeostatic capacity of the body to adapt according to the 
wide variations of intake of dietary magnesium. (17, 18).  
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The site of absorption of magnesium appears to be greatest within the 
duodenum. Illeum also is a major site if absorption. (19). The absorption seems to 
have two mechanisms. One is an active process and other is a passive process. 
When the dietary fibre intake increases, there is a reduction in the amount of 
magnesium that is absorbed by the intestines. (20,21). There is a magnesium 
binding compound in the dietary fibre. These are the phytates. The paradox is that, 
the food that is rich in phytates is also rich in their magnesium content. So there is 
no reduction in body magnesium levels on consuming a high fiber/phytate diet.  
Excretion 
The kidneys have a very important role in the homeostasis of magnesium 
inside the human body. There is active reabsorption of magnesium that takes place 
in the loop of henle. It also occurs in the proximal convoluted tubule. The 
excretion and reabsorption of the ion is very much influenced by the concentration 
of sodium in the urine, It is also influenced by the acid base balance.(23). 
Dietary changes that caused a change in the acid base balance of the urine in 
the favour of alkalosis, resulted in a reduced excretion of magnesium through the 
urine. To be more precise, the urinary magnesium levels dropped by up to thirty 
five per cent.(22).  
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Several other studies show that dietary intake of calcium more than 
2600mg/day, along with a high sodium chloride intake, is responsible for a shift 
towards negative magnesium balance, by increasing its excretion through urine. 
Other routes of excretion of magnesium are via the gastrointestinal tract. 
This is mainly via the magnesium content inside the epithelial cells of the intestine 
that is lost as a normal repair and regeneration process. This is not a significant 
route. Other non-significant route of excretion is via the sweat, during vomiting, 
diarrhoea and other fluid losses. Since much of the magnesium is intracellular, 
these losses do not significantly affect total body magnesium. 
Estimated Allowances of magnesium 
Age Group    Magnesium requirement(mg/day) 
0-6 months      26 
7-12 months      54 
1-3 years      60 
4-6 years      76 
7-9 years      100 
Adolescents (10-18years) 
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Males       230 
Females      220 
Adults(19-65 years) 
Males       260 
Females      220 
65+ years 
Males       224 
Females       190 
One important point to consider is that, there is no increase in dietary 
magnesium needed in case of pregnancy. However, there is a need to increase the 
levels of magnesium consumption during the periods of lactation. The required 
increase is 50mg/day. 
Upper tolerable limit 
 Reaching the upper tolerable limit through diet alone is very much unlikely. 
No case has been reported so far. However there is the possibility of contamination 
of food and water sources with elementary magnesium, most commonly with 
magnesium salts. (24) 
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Age group     Upper limit of magnesium consumption 
Children(1-3 years)     65mg 
Children(4-10 years)     110 mg 
Adolescents       350 mg 
Adults       350 mg 
 
Signs and symptoms of hypomagnesaemia are mostly nonspecific.  The most 
common ones are nausea, diarrhoea and hypotension. The hypotension may be a 
direct effect of magnesium and not always due to dehydration because of diarrhoea 
and/or vomiting. 
Origins of Magnesium deficiency 
Nutritional deficiency that leads to pathological processes and eventually to 
symptoms is infrequent in infants. They are even rarer in adults. 
It is however possible in very rare circumstances. One example of such an event 
would be relatively low magnesium content in diet along with prolonged diarrhoea 
that is severe. Or when dietary deficiency of magnesium is coupled with urinary 
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loss of magnesium, especially if the diet results in reduction in pH levels of urine 
or a relatively acidic urine.  
Other scenarios include the conditions in which there is increased demand 
for magnesium, and the body is unable to provide the necessary nutrient. For 
example, when an individual is getting rehabilitated from general malnutrition with 
macronutrients alone, without the necessary micronutrients, there is increased 
susceptibility to the effects of magnesium deficiency.(16) 
Many studies have been conducted that show that there is a decline in the 
excretion of magnesium via the urine, during protein energy malnutrition (PEM) 
It is also accompanied by a reduced absorption of magnesium through the 
intestines. When one is recovering from protein energy malnutrition sates like 
kwashiorkor and marasmus, we can expect a period of catch-up growth. This is not 
achieved if the dietary magnesium levels are not increased substantially (16).  
Effects of magnesium deficiency  
 The early pathological processes and consequences caused by magnesium 
depletion mostly affect the nervous system. It also effects neuromuscular system. 
The reason behind this is not unclear. It may be because of the influence of 
magnesium on the efflux and influx of potassium between tissues and between the 
intracellular and extracellular compartments.  
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 Decline in the status of magnesium in the body causes anorexia associated 
with nausea as the most common symptom. Other symptoms are lethargy along 
with muscular weakness. Staggering is also seen. If the duration of magnesium 
deficiency is prolonged, it may result in significant weight loss. 
 As the magnesium levels progressively decrease, gradually other symptoms 
appear. These symptoms are generally more bothersome. The primary process or 
pathology in magnesium depletion is hyper irritability or hyper excitability of 
neurons, neuromuscular junctions and the connections between the muscles. It 
means that these cells get exited from their resting membrane potential to give rise 
to an action potential more easily than before. In other words, the threshold for 
excitation is reduced and also the magnitude of the exiting current is also reduced. 
 This leads to muscular spasms and tetany. The severity of these symptoms is 
highly variable. They may be mild and transient to highly disabling. They may 
ultimately lead to convulsions. It is a common medical practice to infuse 
magnesium in cases of eclampsia. This shows the importance of magnesium in 
preventing and also in arresting convulsions. 
 In experimental animals a peculiar observation was made. The animals that 
had a lower magnesium levels in their body were more susceptible to audiogenic 
shock. 
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 Fatal consequences are also seen. These include cardiac arrhythmias and 
pulmonary edema. Cardiovascular mortality is the number one cause of deaths in 
the world. Magnesium levels thus seem to play an important role in such an 
important health condition. 
 Certain studies have suggested that a sub-optimal magnesium status, not 
necessarily a established hypomagnesaemia, may be a risk factor in the etiology of 
coronary artery disease. It may also be a risk factor for systemic hypertension. 
If they are indeed true, more insight and research is needed into the 
relationship between magnesium and the heart. The fact however remains that 
additional evidence is needed to establish a definite link between magnesium levels 
in the body and cardiovascular disease. 
ENZYMES and MAGNESIUM 
ENZYMES 
 Enzymes are complex proteins that are responsible for the catalytic action of 
certain chemical reactions. Generally speaking these are biochemical reactions. 
Most of these biochemical reactions take place inside the body or in-vivo. But as in 
all cases there are exceptions. Bacteria produce enzymes to ferment sugars to 
produce alcohol and carbon di oxide. In fact this was one of the first enzymatic 
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biochemical reactions discovered which paved the way for future research into the 
functions and properties of enzymes. 
  
 
 The above diagram illustrates how an enzyme functions. The enzymes bind 
temporarily with the chemical molecules that are taking place in the biochemical 
reactions. For both of the chemical substances to react with each other, both of 
them much reach a specific energy level called activation energy. What the enzyme 
effectively does is that it reduces the activation energy needed for the desired 
chemical reaction to take place, so the speed of the reaction that occurs in the 
desired direction increase many folds. 
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 The following graphical representation illustrates how the enzyme reduces 
the activation energy that is required for the initiation of a chemical reaction and 
thus speeds up the reaction in one specific direction. 
 
 
Coenzymes and cofactors 
 Cofactors can be considered as a part of an enzyme. In other words, enzymes 
are not always a single molecule. Sometimes it may be formed of multiple sub-
units or parts. The entire enzyme functions optimally or normally only when the 
cofactor part is attached to the other part of the enzyme. 
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 Here the incomplete enzyme without the cofactor can  called as an 
apoenzyme. When the apo- enzyme and the co-factor join together we get the 
completely functioning enzymes called as holoenzymes.  
 One important thing to keep in mind is that the co-factor is not a protein, 
unlike the apoenzyme which is a protein. 
 
 
Coenzymes are different from co-factors. Co-enzymes often act as carriers 
of electrons or carriers of hydrogen ions from one substrate to the other in an 
enzymatic reaction. 
Coenzymes bind to the active site of the enzymes which is involved 
physically in the manipulation and binding of the substrates. Co-factor are the non-
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protein part of the enzyme, which is mostly bound to the inactive site of the 
enzyme, not involved in the binding and release of the substrates that are involved 
in the biochemical reaction. 
 
Prosthetic groups are coenzymes that are bound to an apoenzyme very 
tightly. N most cases there is a covalent bond between the prosthetic group and the 
remaining part of the enzyme. 
 
Cofactors can be divided into two types. 
1. Organic Cofactors 
2. Inorganic Cofactors 
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Organic cofactors include molecules like heme, flavins 
                      
 HEME       FLAVIN 
 
Inorganic Cofactors like metallic ions. 
1. Magnesium (Mg 2+) 
2. Zinc (Zn2+) 
3. Manganese (Mn2+) 
4. Iron (Fe2+) 
5. Iron sulphur clusters. 
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Enzymes requiring magnesium as a cofactor 
 If you count the total number of enzymes that require magnesium as a 
cofactor in the body, in comes to around three hundred.  A complete enumeration 
of these enzymes are beyond the scope of this discussion.  
However we shall brifly describe the most important group of enzymes and their 
functions in the human body 
The Carboxylases 
Carboxylation: Carboxylation as a biochemical reaction in which a carboxyl 
group is attached to a substrate. The opposite process id called as 
decarboxylation. 
Examples include: 
1. Pyruvate carboxylase enzyme 
2. Acetyl CoA carboxylase 
3. Phosphoenol pyruvate carboxylase. 
4. Propionyl CoA carboxylase. 
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 The carboxylases allow the addition of new carbon molecules into the 
substrate from CO2 molecule or HCO3- molecule. They are divided into teo types 
based on cofactor requirement. One type requires biotin and others require vitamin 
K. 
 
One of the important functions of carboxylases in the body is the synthesis 
of biomolecules.  
Carboxylases are involved in fatty acid synthesis, carbohydrate synthesis 
and many other reactions. 
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Pyruvate carboxylase. 
 As shown in the above figure magnesium ions are an important prosthetic 
group or cofactor in the entire carboxylase group of enzymes. This magnesium 
plays an important role in fatty acid production carbohydrate metabolism and other 
important reactions. 
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Transketolases 
 Transketolases are enzymes that play a very important role in the pentose 
phosphate pathway that is present in virtually all organisms including humans. 
Interestingly it is also present in the calvin cycle of photosynthesis. 
 It catalyses two important reactions. 
1. The cofactor of the enzyme, TPP ot thiamine pyrphosphte transfers a two 
carbon segment from a five carbon xylulose to a five carbon ribose to form a 
seven carbon molecule called as sedoheptulose. 
2. The second reaction involves the transfer of the two carbon fragment from 
Xylulose to the four carbon atom containing erythrose, resulting in the 
formation of the six carbon Fructose 6 phosphate and glyceraldehyde 3 
phosphate.  
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 Transketolases are thus responsible for the bio synthesis of NADPH which 
in turn is responsible for many of other synthetic reactions of the human body.  
NADPH is also responsible for the replenishment of glutathione which is 
one of the most important anti-oxidant molecules of the human body. 
 
Transketolase is the connecting link between the pentose pathway and 
glycolysis. The excess of sugar phosphates is thus shunted into the carbohydratr 
pathway. 
Magnesium is an important prosthetic group of the transketolase enzymes 
and is thus indirectly responsible for the anti-oxidant abilities and carbohydrate 
metabolism of the body. 
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Phosphatases 
Phosphatases are enzymes that are capable of removing a phosphate group 
from a substrate. 
 They achieve this by hydrolysing phosphoric acid. After 
hydroxylation, we get a phosphate ion and a molecule with a free hydroxyl group. 
 The action of phosphatases is exactly opposite to the action of kinases 
and phosphorylase, in which a phosphate molecule is added to a substrate from 
high energy molecules like ATP. 
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Importance of phosphatases in human physiology 
The action of a phosphatase is opposite to that of kinases or phosphorylases, 
which in turn add a phosphate group to a protein or enzyme. The process of 
addition of an enzyme may result in activation of the enzyme or deactivation of the 
enzyme. It may also result in a protein to protein interaction. 
Phosphatases are thus important in many of the signal transduction 
pathways.   
Phosphorylation of proteins plays an important role in many biological 
functions. These include: 
1. Metabolism, 
2. Gene transcription, 
3. Gene translation, 
4. Cell-cycle progression, 
5. Cytoskeletal rearrangements 
6. Protein protein interactions 
7. Cell movement 
8. Apoptosis. 
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Magnesium is an essential component of the phosphorylase group of 
enzymes. So magnesium is essential in all the biological processes 
enumerated above. 
Memory and learning 
 In the adult brain, protein phosphorylation is involved in many neuro 
biological processes. Dysfunction of the enzyme has been linked to various 
neurodegenerative processes and cognitive degeneration. 
 
Peptidases 
 Peptidases are also known as proteases. They are responsible for the 
cleavage if protein molecules or peptide molecules. 
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 Examples of proteases in the human body. 
1. Digestive system. Pepsin, trypsin, are some of the proteases that are 
present in the digestive juices of the human body . These are invaluable 
in the proper digestion, and nutrition of the human body. 
 
2. Haemostasis: Many of the protease enzymes are present in the serum of 
human body. They are activated in the event of haemostasis and also in 
lysis of the clot that is formed. Some of the examples of such protease 
enzymes in the serum are, thrombin and Hageman factor. These are 
involved in blood clotting. Plasmin is also a protease enzyme. It is 
involved in clot lysis . 
 
3. Leucocytes: Many proteolyic enzymes are present in the leucocytes. 
Leucocytes are responsible for the immune mechanism of the body. 
Some of the protease enzymes that are present in leucocytes are, elastase 
and cathepsin G. Elastase functions as the enzyme that acts on the elastin 
protein. 
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 Magnesium is a prosthetic group of the protease group of enzymes, without 
which, these enzymes will not function properly. So magnesium ions are also 
essential for the above mentioned life processes. 
 
 
Adenylyl cyclase 
 These are a class of enzymes. All classes of these enzymes are involved in 
catalysing the conversion of ATP (Adenosine Tri Phosphate) to cAMP or cyclic 
Adenosine Mono Phosphate. 
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 The cyclic AMP thus produced have a special role. They act as a secondary 
messenger or as a regulatory signal by binding to certain cAMP binding proteins. 
These proteins may be enzymes or transcription factors. 
 For example in the sympathetic system, adrenaline binds to the beta 
receptors located on the cell membrane. The beta receptor is a G protein coupled 
receptor. As the receptor binds to the ligand, the enzyme adenylyl cyclase is 
activated, resulting in the production of cAMP or cyclic amp molecules which bind 
to certain cAMP binding proteins intracellularly and thus propagates the cascade of 
intra-cellular changes. 
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 The adynelate cyclase enzymes are usually coupled to G-Protien receptors. 
The G protein couple extracellular receptors are essential for all the cells are they 
enable those cells to communicate signals between other cells and also the external 
environment.  
 The messengers reaching the extracellular receptors need to transfer the 
message to the intracellular organelles. His is accomplished by the adenylate 
cyclase enzyme and the cyclic AMP based secondary messenger system. 
 Magnesium is an important cofactor of the adenylate cyclase enzyme.  
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Ribonuclease  
 Nucleases are enzymes that catalyse the degradation of nucleic acids into 
smaller components. There are mainly two types of nucleic acids. DNA(De- oxy 
Ribonucleic acid) and RNA(Ribonucleic acid). 
 Ribonucleases are enzymes that are involved in the degradation of RNA or 
ribonucleic acid into smaller components. 
There are two types of ribonucleases. 
1. Exonucleases 
2. Endonucleases 
 
Structure of RNAase A 
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Functions: 
 All of the living things studied contain many RNAses of many different 
types., showing that the process of RNA degradation is evolutionary very ancient 
and important. Apart from cleaning of cellular RNA that is not  required an longer. 
RNases play important roles in the complete development and maturation of of all 
RNA molecules, both messenger RNAs that carry genetic information for creating 
proteins, and also  non-coding RNAs that that have different cellular functions. 
Apart from this, RNA degrading enzymes  are a first line of defence against RNA 
viruses that may invade the cell and take over the cellular machinery and multiply.. 
Some animal cells, interestingly secrete large amounts of of non-specific 
RNases like T1 and A. RNases are, thus, very common. This results in very short 
lifespans for RNAs. Except for the RNAs that  are in a protected and safe 
environment. One should not that that all intracellular RNAs are protected from the 
activity of RNA ase  by different types of methods. These methods include 5' end 
capping, 3' polyadenylation.  RNA may fold inside a protein RNA comples to 
escape the ribonucleases. 
Magnesium is essential to the functioning of the ribo-nuclease enzyme. 
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Kinases 
Kinase is the enzyme which functions as the one which transfers high energy 
phosphate molecules from high energy molecules like Adenosine tri 
phosphate(ADP) to the substrate.  
 
 
 
The process performed by kinases is known as phosphorylation. 
Kinases should not be confused with phosphorylases. Phosphorlylases add 
inorganic phosphates to the substrates that are not derived from high energy 
molecules like Adenosine Tri Phosphate, Guanidine Trti Phosphate etc. 
 Whether a biological molecule is phosphorylated or not, whether it may be a 
protein, carbohydrate or lipid may affect its reactivity or its tendency to undergo or 
ivolve itself in a chemical reaction.  
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Kinases carry out the transfer of a phosphate ion from a high energy molecule like 
ATP to another molecule which is the substrate. Kinases are essential to make this 
reaction stable because the phosphoanhydride bond is a very high energy bond. 
Kinases cause proper orientation of the substrate and the phosphoryl group. This 
happens inside their active sites. This in turn increases the reaction speed. In 
addition to this, they frequently use amino acid residues that are charged 
positively. This causes electrostatic stabilization of the transition state. by 
interacting with the phosphate groups that are having a negative charge. In an 
alternate method, some kinases make use of metallic cofactors which are inside 
their active sites. They in turn coordinate the phosphoryl groups. 
Kinases are utilized widely in transmitting certain signals and also to regulate 
processes inside cells. Phosphorylation of biological molecules can increase or 
decrease their activity and regulate their ability in interacting with other bio-
molecules. The adding and removing of phosphate groups gives the cell an ability 
to control. This is due to the fact that different kinases respond to different signals 
or conditions. Mutations of kinase enzymes that may lead to a loss of function or 
increase in function can cause malignancy and other illnesses,including some kinds 
of leukemia, spinocerebellar ataxia (type 14). 
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 Magnesium is the cofactor for the kinase group of enzymes.   
 
Magnesium and the heart 
Role of Magnesium in Myocardial Cell Functions 
 In the myocardium of mammals, the concentration of magnesium is in the 
sub millimolar range. It varies between 0.3-0.8 millimoles/litre. (27). It is the 
second most cation, present intracellularly in humans. 
A significant amount of magnesium ions are bound to high energy phosphate 
molecules and also to phospholipids of the cell membrane, inorganic acids, 
proteins or enzymes. (28).Changes of magnesium concentration intracellularly 
leads to important effects in the proper functioning of the second messenger 
systems and ion channels of cardiac cells. Magnesium activates or acts as a catalyst 
in more than 300 enzymes that are involved in biochemical reactions. It thus 
functions as  a metallocoenzyme. (28, 29) 
 The Na+/K+ -ATP ase pump requires magnesium for proper functioning. 
The Calcium gradient of the cardiac myocyte is maintained partially by the Mg2+ 
dependent Ca2+- ATP ase system. 
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 There is increasing evidence suggesting that magnesium modulates the 
cation channels of the sarcolemma, thus exerts a very important and fundamental 
influence on the electrical function and also the contractile function of the 
myocardium. (30). 
 Thus we can see that manifest or hidden magnesium deficiency can make 
the atrial and ventricular myocardium electrically unstable and increases its 
tendency to produce dangerous arrhythmias.(31,32).  
When there is myocardial ischemia or infarction, the affected myocardial region 
also losses magnesium in addition to other ions. But newer data suggests that there 
is a threefold increase in the intracellular levels of magnesium during global 
ischemia.  
 After hospitalisation approximately thirty per cent of patients with acute 
myocardial infarction have hypomagnesemia and it may play a role in the 
development of hyperexitability of the myocardial tissue. (33,34,35). 
 The cause of this is proposed to be enhanced lipolysis that occurs in patients 
of acute myocardial infarction, caused by an excess of circulating catecholamines. 
This increases the free fatty acid levels in blood. They form complexes with the 
magnesium ions. This is followed by the deposition of “Mg2+ soaps” in the fat 
cells. (35) 
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 There is epidemiological data suggesting that the incidence of coronary heart 
disease is higher in the areas where the soil is deficient in magnesium and also in 
area where the drinking water is soft. There is also consensus that reduced 
magnesium content in potable drinking water is linked with increased rates of  
Sudden cardiac deaths. 
Electrophysiological Effects of Magnesium 
 The functions of Magnesium and potassium are very closely related. (36,37). 
Potassium loss is almost invariably associated with magnesium depletion. 
Hypomagnesemia is present in 40 per cent of the disease conditions involving low 
potassium levels in blood. (36). Hypopotassemia can only be corrected if 
magnesium is administered simultaneously with potassium. (37,38) 
 Electropharmacological effects of magnesium were identified experiments 
on isolated individual cardiac fibres and isolated cells with different types of in 
vitro techniques.  The most noteworthy effects of magnesium are those which are 
exerted on potassium conductance and repolarising potassium currents. (30,35). Of 
all the potassium currents recognised, potassium has a tendency to flow into the 
cell cytoplasm rather than flow outwards into the extracellular fluid. This is 
because intracellular magnesium is a potent blocker of cardiac potassium channels. 
If there is an electrochemical gradient that favours outward flow of potassium, 
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magnesium ions blocks the potassium channel preventing the outward flow of 
potassium. Thus potassium channels acquire the property known as inward 
rectification. It is very important in maintaining the plateau of the action potential 
generated in the cardiac cells. (27). 
 Magnesium influences the slow inflow of calcium ions through the     L-type 
of calcium channels. It is also a modulator of intracellular calcium in the 
sarcoplasmic reticular system. (36). When there is an increase or decrease of 
magnesium ion levels within the physiological limits, there is a corresponding 
inhibition or enhancement of the calcium inflow(I Ca).  Thus magnesium regulates 
the calcium channel function and regulates the trans membrane calcium inflow. 
(27).  
 The cardiac cells of the nodal regions (Atrioventricular node, Sinoatrial 
node), have a characteristic calcium dependent depolarising mechanism. It is of a 
“slow response type”. As magnesium blocks the inflow of calcium ions it plays an 
important role in controlling these nodal regions. 
 Magnesium can be considered as “nature’s physiological calcium channel 
blocker”. Even though this statement is apparently simplistic, it can be considered 
to be essentially true. (36) 
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 It is also an important fact that the sarcolemma is permeable to magnesium. 
But the mechanism by which magnesium enters the cell through a supposed 
magnesium channel and how it gets removed from the cell through a sodium-
magnesium exchange trans-membrane protein are not clearly identified. (27). 
 It can be considered that the anti-arrhythmic action of magnesium is much 
more complex than previously considered. The conductance of calcium and 
potassium in the cell membrane are all controlled and influenced by magnesium. It 
also regulates the Calcium flux at the level of the sarcoplasmic reticulum. 
  Arrhythmia mechanisms suppressible by magnesium 
 The established mechanisms of arrhythmia generation were re-entry and 
automaticity. The third mechanism that plays an important role in arrhythmia 
production and propagation is afterdepolarizations leading to triggered activity. 
Afterdepolarisations occur during the course of repolarisation. These are called as 
early afterdepolarisations or EAD’s. (39). If afterdepolarisations occur after the 
action potential is completed, that is during phase 4 of the action potential, they are 
called as delayed afterdepolarisations. (DAD).  
 Recent experiments are highly indicative that, early afterdepolaristions and 
delayed afterdepolarisations and the triggered rhythms caused by them can be 
stopped by magnesium. The tachycardias caused by this phenomenon can be 
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terminated by addition of magnesium in in-vitro experimental studies. (41). 
Injection in-vivo also suppresses these mechanisms.  
This is true despite the mechanisms behind early afterdepolarizations and delayed 
after depolarisations are different.  EAD is caused by enhanced calcium inflow 
through the L type of calcium channels. Contributory effects are also made by 
sodium ions flowing through the non-inactivating sodium channels. (40). The 
emergence of EAD is helped by a prolonged duration of the action potential. Early 
after depolarisations have been most commonly observed in the purkinje cells of 
the heart of mammals which has the longest duration of the action potential. It is 
also known as APD. (39).   
EAD are caused primarily by certain substances that lengthen the duration of 
the action potential. Other risk factors include bradycardia or any pauses in the 
heart rhythm. Other compounds include drugs like quinidine, barium, aconite, Bay 
K 8644. 
Magnesium extinguishes the early after depolarisation that occur during the 
phase 2 or plateau phase of the action potential. It accomplishes this by mainly 
inhibiting the inflow of calcium. But apart from this it also influences the EADs 
which arise during the phase 3 of membrane potentials which are more negative 
than -60 millivolts and are modulated by sodium currents. (41). 
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 The typical example of the arrhythmia in clinical practice based on early 
afterdepolarisation is the pause dependent “torsade de pointes” ventricular 
tachycardia which is associated with a long QT interval which may be drug 
induced or toxin induced. 
 The Delayed afterdepolarisations can be thought of as a result of oscillations 
of the resting membrane potential of myocytes. These heart cells may be 
overloaded with calcium ions or they may have decreased conductivity to 
potassium ions. This leads to activation of a non-selective, inward, transient flow 
of cations. It also activates the Na+-Ca2+ exchanger. Delayed after depolarisations 
can be created artificially in cardiac preparations by catecholamines, digitalis 
toxicity, caffeine, theophylline, histamine, lysophosphatidylcholine. This DAD 
triggers the activity that is responsible for arrhythmias. This is suppressible by 
magnesium.  
 When there is a deficiency or excess of magnesium in the body, there are 
alterations in the ecg recordings. These are expressed primarily in the calcium 
dependent SA nodes and AV nodes. Myocardial depletion of magnesium enhances 
the automaticity of the sinus node. Supplementation with magnesium has a 
negative chronotropic effect. (42). Magnesium also prolongs the PR interval by its 
action on the AV node. It accomplishes this by lengthening the Atrioventricular 
nodal refractory period. Magnesium does not seem to have significant actions on 
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the His-purkinje conducting system. Magnesium does not increase the  refractory 
period of the atrial myocardium or the ventricular myocardium.  
  Electrocardiographic changes in magnesium deficiency include ST segment 
depression, flattening of T wave and QT prolongation. It is difficult to say if it is a 
direct effect of magnesium inadequacy or due to a co-existing hypopotassemia.  
When there is hypermagnesemia, there is bradycardia, as a result of negative 
ionotropic action. There is prolongation of the PR interval. There may be 
intraventricular conduction abnormalities. The QRS complex is widened. The T 
waves are sharper and higher.  
  
Treatment of arrhythmias of the heart with magnesium 
Many of the arrhythmias of the heart can effectively and successfully treated 
with an appropriate dose of I.V magnesium chloride or magnesium Sulphate. This 
anti arrhythmic effect was reported first by Zwillinger in 1935. Eight patients were 
administered I.V magnesium sulphate for ventricular tachycardia caused by 
digitalis toxicity. Sinus rhythm was successfully attained in all these patients. 
Hypomagnemia (nineteen per cent)  is more common than hypokalemia (ten per 
cent) in patients that are treated with digitalis and digitalis preparations. The 
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Sensitivity of the myocardial fibres to cardiac glycosides is also increased in the 
cardiac myocytes because of intracellular depletion of magnesium ions. 
 Ouabain- induced sustainable monomorphic ventricular tachycardia 
can be terminated by flunarazine which is a calcium overload inhibitor. It can also 
be inhibited by magnesium. 
 It was believed for a long time that the cause for this protective action 
was because of the reactivation of the digitalis blocked sodium potassium ATP ase 
pump in the sarcolemma. Later studies proved that Magnesium does not increase 
the activity of this enzyme. Instead of this, it exerts a direct effect in the 
membranes and modulates the outflow of potassium and cellular loss of potassium 
in the presence of digitalis.  
Another arrhythmia in which magnesium is invaluable as a treatment 
modality is the treatment of polymorphic ventricular tachycardia or torsades de 
pointes. This arrhythmia often accompanies the long QT syndromes. This 
ventricular tachycardia is peculiarly bradycardia dependent. It is refractory to most 
other anti-arrhythmic therapy. As a matter of fact it may even be induced by other 
anti- arrhythmic drugs. The commonest drugs are  the Class Ia or Class III drugs. 
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The first reports of successful therapy of this arrhythmia with magnesium 
were reported during the early 1980s. At this time its mechanism of action was not 
known widely or not at all.  
Torsades de pointes can very often be terminated by Intravenous 
magnesium, especially when the QT interval has not yet been significantly 
shortened or if the QT interval is only shortened to a very small extent. (43). 
 
Intravenous magnesium was also found to be proven useful in the treatment 
of barium and organophospherous compound - pesticide induced arrhythmias in 
the clinical as well as in the experimental setting. 
The initial dose of magnesium(Mg2+)  is 1-2 grams. It is given as an I.V 
bolus during 1-2 minutes.. It can be repeated within 15 minutes. It is followed by a 
maintenance dose of 3mg-20mg/minute infusion for 6 hours to two days. 
Maintenance dose is necessary as it has a very fast renal elimination. 
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Arrhythmias suppressible by I.V MgSo4 
Proven Use: 
“Torsade de pointes” Ventricular Tachycardia 
Digitalis toxicity-induced tachycardias 
Magnesium deficiency-induced atrial fibrillation 
 
Accepted use: 
Ventricular extrasystoles/VT associated with Myocardial Infarction. 
Multifocal atrial tachycardia 
 
Investigational: 
Re-entrant supraventricular tachycardias 
Arrhythmias in mitral valve prolapse. 
Sustained monomorphic Ventricular Tachycardia. 
Postischemic/reperfusion arrhythmias 
80 
 
 
In the early stages of Myocardial infarction, there is transient 
hypomagnesemia, which may last for up to 48 hours. Abraham et al. performed a 
placebo-controlled, double-blind study on ECG that was continuously monitored in 
myocardial infarction patients, and found that the incidence of complicated 
ventricular arrhythmias was lesser in those patients treated with magnesium, than 
in the placebo-treated group. Rasmussen et al. administered magnesium ions on the 
second. The proportion of arrhythmias in group treated with magnesium was 21% 
and in the placebo group was 47%. 
 LIMIT 2 (Leicester Intravenous Magnesium trial) confirmed the above 
studies. But the ISIS-4 trial showed no benefit in using magnesium during the 
treatment of acute myocardial infarction. However in ISIS-4 trial, magnesium was 
administered after the administration of fibrinolytic therapy. 
  Magnesium ions can terminate post Myocardial infarction sustained 
monomorphic Ventricular tachycardia. Allen et all. reported that intravenous 
Magnesium Sulphate stops sustained monomorphic ventricular tachycardia 
accompanying organic heart disease. (44). 
 Intravenous magnesium is recommended in atrial fibrillation associated with 
alcoholic disease forms like holiday heart syndrome and atrial fibrillation seen in 
delirium tremens. (36). Prophylaxis with magnesium was found to be useful in the 
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prevention of atrial fibrillation in post-operative patients of coronary artery bypass 
grafting. 
 Intravenous Magnesium can be applied effectively in re-entrant 
supraventricular tachycardia) using an AV nodal circuit or using an AV accessory 
pathway. The verapamil like effect of intravenous magnesium upon the 
atrioventricular node in Supraventricular tachycardia is in accordance with the 
calcium antagonistic activity of magnesium ions. Magnesium also has 
parasympathtomimetic and antiadrenergic actions of magnesium. However, 
intravenous magnesium sulphate is less effective than adenosine or adenosine 
triphosphate in stopping supraventricular tachycardias. The side effects like 
nausea, flushing and headache are relatively more severe after the use of 
magnesium. So in the current setting magnesium sulphate has little role in the 
clinical management of supraventricular tachycardia.  
Magnesium deficiency most likely plays an important role in the 
development of the hyperexcitability of neuromuscular connections frequently 
seen in the syndrome of  idiopathic mitral valve prolapse. Magnesium therefore has 
an important place in preventing cardiac arrhythmias that are associated with 
mitral valve prolapse, partly due to its pharmacodynamic action and partly for the 
purpose of substitution to eliminate any hidden tetany. In this area, further 
investigations are required and more experience must be attained. 
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Materials and methods 
 
Type of study: Case control study. 
The study population:  
Male patients who presented to Intensive Coronary Care Unit and were diagnosed 
as acute ST segment myocardial infarction. 
The control population: 
The group consisted of random young male population with no history of any 
significant illness the recent or remote past. 
 
Total number of cases: 70 
Total number of controls: 30 
 
The cases were divided into three subgroups. The division was according to the 
age of the patient. 
1. Subgroup A: Age less than 45 years 
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2. Subgroup B: Age between 45 to 55 years 
3. Subgroup C:  Age more than 55 years 
Diagnosis and the investigation of the cases:   
Diagnosis:  
Patients, who came to the Intensive coronary care unit with symptoms 
suggestive of acute myocardial infarction, were evaluated. 
A thorough history was elicited from the patient and the relevant clinical 
examination was performed.  
A standard twelve lead Electrocardiogram was done in all of those patients. 
The ECG was analysed for the presence of acute ST elevation Myocardial 
infarction. 
ECG criteria for diagnosing STEMI: 
o New onset ST segment elevation more than 1millimeter in limb leads 
and/or more than 2 millimetre in precordial leads.  
o There ST segment elevation should be present in two or more leads.  
o The two or more leads should be contiguous with respect to each 
other. 
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After the interpretation of ECG the patients were planned to be included in 
the study population if they fulfilled the ECG criteria for STEMI, if they 
satisfied the additional inclusion criteria for the cases and if they did not fall 
into the exclusion criteria. 
Inclusion criteria:  
o Male patients. 
o Patients who has symptoms of acute myocardial infarction. 
o Patients who satisfy the ECG criteria for diagnosis of acute STEMI. 
o Patients who presented within twelve hours after the onset of 
symptoms. 
o Patients who consented for being included in the study. 
Exclusion criteria 
o Female patients  
o Patients with previous history of ischemic heart disease 
o Patients with previous history of hypertension 
o Patients with previous history of diabetes mellitus. 
o Patients with previous history of dyslipidemia. 
o Patients who are on medications like diuretics for any disease 
conditions. 
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Procedure done 
1. Obtaining informed consent from the patient for the study 
2. Approximately 4 ml of venous blood was collected from the patient. 
3. The time interval between admission and the drawing of blood did not 
exceed 6 hours. 
4. The blood drawn was transferred to plain blood collection bottle without 
any anticoagulants. 
5. Appropriate labelling was done. 
6. The Performa for each individual case was filled promptly as soon as the 
above steps were being undertaken. 
7. The blood collected was send to the biochemistry laboratory. 
8. The blood soon separated into the serum and the fibrin clot. 
9. The blood was centrifuged at 2000 rpm for complete separation of the 
serum from the blood. 
10. The serum thus obtained was estimated for its magnesium concentration 
using colorimetric method.   
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A total of seventy cases who met the inclusion criteria were investigated for 
serum magnesium levels over a period that extended from October 2013 to 
August 2014.  
 
Method for magnesium estimation 
Colorimetry 
It is the technique used to determine the concentration of coloured solutes in 
a solution. 
A light of known wavelength and intensity is passed through the coloured 
solution. There is a change in the wavelength and maybe the intensity of the 
light beam after the light passes through the solution. This light and its 
properties are detected by a spectrophotometer. The change in the the 
property of light emitted and detected is proportional to the intensity of the 
colour in the solution. The intensity of the colour is directly proportional to 
the concentration of the solute. Thus, indirectly we can estimate the 
concentration of the dissolved compound. 
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Calmagite Method 
Calmagite is a complex chemical compound. It is wine red in colour when it 
is combined with a metal ion like Mg2+ and blue in colour when it is not combined 
with a metal ion. 
 
Principle: 
Magnesium combines with Calmagite in an alkaline medium to form a red 
coloured complex. Interference by calcium and proteins is eliminated by the 
addition of specific chelating agents and detergents. The intensity of the colour 
formed is directly proportional to the amount of magnesium present in the sample. 
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Magnesium + Calmagite  Red coloured complex. 
Normal reference values: 
Serum (Children) : 1.5 – 2.0 mg/dL 
 (Adults) : 1.5 to 2.5 mg/dL 
CSF   :2.0 to 3.0 mEq/dL 
Urine   :6.0 to 8.5 mEq/dL 
Sample material: 
Serum that is free from haemolysis. Magnesium is reported to be stable in 
serum/plasma for 7 days at 2-8 degree celcius. 
Procedure: 
Wavelength/filter: 510 nm (Hg 546nm)/Green. 
Temperature: Room temperature. 
Light Path: 1 centimetre. 
Incubation time: 5 minutes. 
 
 
Alkaline Medium 
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Linearity: 
 The procedure is linear upto 10mEq/L. If Values exeed this limit, dilute the 
sample with distilled water and repeat the assay. Calculate the value using an 
appropriate dilution factor. 
Calculations:  
Magnesium in mEq/L = (Abs.T/ Abs.S) x 2 
2 mEq/L =2.44md/dl. 
 
   Data collection and analysis 
 When the case is selected to be included in the study, the Performa is filled 
out for each case. The Performa contains important information like the age of the 
patient, duration of symptoms, time interval between hospital administration and 
sample collection, the severity of myocardial infarction, and the follow up details 
of the patient for his duration of hospital stay. 
 The entire data is tabulated and analysed.  The information we are looking 
for is the presence and prevalence of hypomagnesemia in the study population. If it 
90 
 
 
is prevalent we use various statistical methods to determine if the prevalence level 
can be considered significant or not.  
 We also compare the mean blood magnesium levels of the study population 
and the control population. If there is any difference between the mean magnesium 
levels, we try to determine if the difference is statistically significant by calculating 
the P value for the data set. 
 After obtaining the results, we shall compare the observations and results 
with previous studies of similar nature which have been published in popular 
medical journals. We look if there is an agreement between my study and the 
previous studies. If there is no agreement we shall make an attempt to discuss the 
reasons for the difference in outcome. 
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Observations and results. 
 
Total Number of cases =70 
Total number of controls = 30 
 
 Subgroup A (Age<45) 
 Subgroup B (Age45-55) 
 Sub group C ( Age >55) 
 
 Subgroup A n=22 
 Subgroup B n=24 
 Subgroup C n=24 
Case distribution According to Age 
Subgroup A
Subgroup B
Subgroup C
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Age comparison 
 
Mean Age of the cases = 50.83 
Mean Age of the control group = 28.53 
 
 
 
 The control group were considerably from a younger population. 
 The cases generally belonged to the middle age as myocardial infarction 
occurring for the first time is essentially more common in that group 
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Mean age of the Subgroups. 
 
Subgroup A- 37.5 
Subgroup B-49.87 
Subgroup C-63.96 
 
 
 
 Within the subgroups, the cases were distributed favourably and there was 
homogeneity in distribution. 
 There was no clustering of cases towards a specific age group.  
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Prevalence of hypomagnesemia in the study population 
Defining Hypomagnesemia: Cases who have a serum magnesium levels of less 
than 1.5milligrams per one hundred millilitres (<1.5mg/100ml) of blood. 
Total number of cases =70  
Total number of cases with hypomagnesenia = 1 
Patient name - Murugan  
 Age 38 -years 
 Diagnosis – Acute inferior wall ST elevation myocardial infarction. 
 Serum Magnesium Levels – 1.2mg/100 ml. 
 Outcome –No immediate or long term complications.  
Prevalence of Mypomagnesemia in the Study population   
=        Number of patients with hypomagnesemia        X        100 
                        Total number of cases  
=                        1 X 100 
                              70 
=  1.42 % 
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Prevalence of hypomagnesemia = 1.42 % 
Significance of the finding 
 
 Magnesium is normally distributed in the general population. 
 The “normal levels” of magnesium (1.5-2.5 mg/dl) apply only to the 
population that lie inside two standard deviations from the mean, or to the 
population that lies within 95% confidence interval. 
 If the prevalence is significant, it must be more than 5%. 
Conclusion: The prevalence of hypomagnesemia in the sample population is not 
significant. 
 
Prevalence of hypomagnesemia in Study 
population. 
Hypomagnesemia
Normal Magnesim Levels
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Mean levels of Magnesium in the cases and controls.  
Cases(n=70) : 2.009 
Controls(n=30) : 2.177 
 
 
As the above data and bar diagram depicts, the mean levels of magnesium is lower 
in the acute myocardial infarction patients, when compared to the  healthy young 
control population. 
Now we shall see if the above difference is statistically significant. 
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Sr. Mg for Case and Control 
  
     
 
Mean SD p' value 
 
Case 2.009 0.303 0.013 Significant 
Control 2.177 0.311 
   
Mean value of the cases = 2.009  
Mean value of the controls = 2.177 
Diffeence between the means = 0.168 
Standard deviation of the cases = 0.303 
Standard Deviation of the controls = 0.311 
 
 
Standard error of difference between the two means 
=  
 (SD1)^2  + (SD2)^2 
     n1      n2  
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= 
 0.0013  + 0.0032 
 
 
 
Standard error of difference between the two means  = 0. 067. 
 
If the result is significant, two times the standard error of difference between the 
two means will be less than the actual difference between the two means. 
 
So, 2 X Std. error of difference = A= 2X0.067 = 0.134 
Difference between the means  = B                   = 0.168 
 
So, A< B, 
 
So the difference is significant 
 
Conclusion.:  
The mean levels of serum magnesium in acute myocardial infarction patients at the 
time of admission is significantly lower than that of the control population. 
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Comparison between the various subgroups. 
 
Mean value of Serum Magnesium levels: 
Subgroup A- 1.98 mg/100 ml 
Subgroup B – 2.04 mg/100ml 
Subgroup C –2.00 mg/100 ml 
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Tests for significance: 
Tabular column 
 
Sr.Mg Mean SD p value   
< 45 1.98 0.35 <0.01  Significant 
45 – 55 2.04 0.31 0.83    Not significant 
> 55 2 0.26 <0.01  Significant. 
 
 
 Subgroup A had significantly low levels of mean magnesium levels when 
compared to the controls 
 Subgroup B had lower levels of mean magnesium levels but it was not 
statistically significant 
 Subgroup C had significantly lower levels of magnesium levels when 
compared to the control group 
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Subgroup A – mean =1.98 
Control group- mean = 2.18 
 
Difference between the two means = 2.18 – 1.98 = 0.2 mg/dl (B) 
Standard error of difference between the two means = 0.09 mg/dl (A) 
If the result is significant, two times the standard error of difference between the 
two means will be less than the actual difference between the two means 
So,  
2 X (Std. error of difference) = 2X A = 0.18 mg/dl 
       Difference between the means = 0.2 mg/dl. 
[0.18is less than 0.2] 
Conclusion: The difference is statistically significant. 
1.85
1.9
1.95
2
2.05
2.1
2.15
2.2
Subgroup A Control
Serum magnesium. (mg/100ml) 
Serum magnesium.
(mg/100ml)
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  Subgroup B – mean = 2.04 
Control group –mean = 2.18                
 
Difference between the two means = 2.18 – 2.04 = 0.14 mg/dl (B) 
Standard error of difference between the two means = 0.085 mg/dl (A) 
If the result is significant, two times the standard error of difference between the 
two means will be less than the actual difference between the two means 
So,  
2 X  (Std. error of difference) = 2X A = 0.17 mg/dl 
       Difference between the means = 0.14 mg/dl. 
[0.17 is not less than 0.2] 
Conclusion: The difference is NOT statistically significant. 
1.95
2
2.05
2.1
2.15
2.2
Subgroup B Controls
Serum Magnesium (mg/dl) 
Serum Magnesium (mg/dl)
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Subgroup C – mean = 2.0 
Control group – mean = 2.18 
 
Difference between the two means = 2.18 – 2.00 = 0.18 mg/dl (B) 
Standard error of difference between the two means = 0.077 mg/dl (A) 
If the result is significant, two times the standard error of difference between the 
two means will be less than the actual difference between the two means 
So,  
2 X  (Std. error of difference) = 2X A = 0.154 mg/dl 
       Difference between the means = 0.18 mg/dl. 
[0.154 is less than 0.18] 
Conclusion: The difference is statistically significant. 
1.9
1.95
2
2.05
2.1
2.15
2.2
Subdroup C Conrols
Serum Magnesium(mg/dl) 
Serum
Magnesium(mg/dl)
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Discussion 
Strengths and weaknesses of the study design 
Strengths 
1. The ease of defining the study population- The diagnosis of ST segment 
myocardial infarction is relatively simple 
2. Reduction of confounding factors: The study population was relatively 
homogenous. None of the patients had previous history of coronary heart 
disease. None of them had any treatment with diuretics which could 
drastically alter the serum magnesium levels. Furthermore the study 
population were not also known cases of diabetes mellitus or hypertension 
which can also have an effect on the results. 
3. The relative ease of the procedure performed: Patient is not put through any 
additional difficulty to be a part of this study. The blood samples taken for 
the test were mostly from a portion of the blood sample taken for routine  
investigations . 
4. The objective nature of the result obtained: The result obtained is the 
concentration of  magnesium ions in the blood of the patients. There is no 
need for questionnaires. The result is not influenced by the subjective 
variation of neither the patient nor of that of the examiner. 
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Weaknesses 
1. Relatively Small size of the study population: The number of cases decided 
to be included in the study was 70. The number of controls was 30. This 
study was completed over a period of twelve months. The inclusion criteria 
was stringent. It was difficult to find out a case of myocardial infarction 
without the frequent co-morbid conditions of hypertension and diabetes. As 
the number of cases decreases, more the sample becomes non representative 
of the general population. 
2. Variation in time interval of collecting sample: All of the samples were 
collected within six hours of admission into the hospital. Even though the 
time interval is relatively short, the internal environment of the patient in 
that acute condition can vary significantly, especially regarding the 
circulating catecholamine levels, thus affecting the magnesium content. 
3. Some samples were collected after fibrinolytic therapy: In our institution, the 
door to needle time of one hour is strictly adhered to. As previously 
mentioned, the time interval within the sample was upto six hours. So, the 
action of the fibrinolytic therapy can also affect the levels of magnesium in 
the blood, as the primary pathological mechanism is reversed. But to look on 
the positive side, in all these patients, myocardial necrosis was universal 
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according to the definition. Thus, a high degree of homogeneity was still 
preserved. 
Previous Studies 
Before we dive into the discussion of the results obtained, let us review the 
results and conclusion of previous studies on this topic of serum magnesium levels 
in acute myocardial infarction patients. 
1. Serum magnesium in Acute Myocardial infarction:  Acta Medica 
Scandinavia. Volume 206, Issue 1-6 pages 59-66, December 1980. 
                                                                              -Thomas Dyckner 
 
During the one and a half years of the study, 342 patients with acute 
myocardial infarction were treated at Serafimerlasarettet. The Acute MI 
group had significantly lower serum magnesium levels than a reference 
group. The incidence of Ventricular ectopics, Ventricular tachycardias 
and Ventricular fibrillation were significantly higher in the 
hypomagnesemic patients. 
2. Magnesium and Acute Myocardial Infarction.Transient 
Hypomagnesemia Not Induced by Renal Magnesium Loss. 
Arch Intern Med. 1986;146(5):872-874. 
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 H. Sandvad Rasmussen, MD; P. Aurup, MD; S. Hojberg, MD 
Blood and urine samples were taken during the time of admission. Urine 
samples were taken every 8 hours for the next 7 days. Both urine and 
blood magnesium were analysed. 13 patients were found to have MI. 11 
normal people were taken as controls. The acute myocardial Infarction 
patients had significantly lower levels of serum magnesium. The urine 
concentration of magnesium did not increase with time. This shows that 
the hypomagnesemia is not due to the renal loss of magnesium. The 
mechanism is due to a shift from the extracellular compartment. Maybe 
due to sequestration with the increased levels of free fatty acids. 
3. Serum Magnesium and Potassium in Acute Myocardial Infarction. 
                             Arch Intern Med. 1987;147(3):465-469. 
-Henryk Kafka, MD; Lorrie Langevin, RN. 
   
Over a period of 13 months, serum magnesium and potassium levels 
were measured in 590 patients admitted in a coronary care unit. 
Hypokalemia occurred in 17% of the patients. However 
hypomagnesemia occurred in only 4% of the studied group. However it 
was still a higher incidence than the reference population. Ventricular 
arrhythmias occurred in ten of the thirteen patients with myocardial 
infarction and hypomagnesemia. However the mean levels of serum 
magnesium levels in the normal healthy population was significantly 
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higher than the reference levels. So the findings in this study may not be 
applicable to outside population because of higher magnesium content of 
soil in the selected study area of south eastern Ontario. 
So in most of the studies conducted above, there is enough evidence to state 
that there is transient hypomagnesemia in acute myocardial infarction patients. 
Reference of literature also mentions that the incidence of hypomagnesemia in 
acute myocardial infarction may be upto 30%.(29). 
In this study, the prevalence of hypomagnesemia in the studied cases was 
very low to be of any significance. The patient who developed hypomagnesemia  
did not develop any short term or long term complications. . However the mean 
serum magnesium levels of the cases were significantly lower than that of the 
control population. 
So this study does not agree with most of the studies conducted previously 
regarding the significant prevalence of hypomagnesemia in acute MI patients.  
The reasons for this result obtained are not exactly clear. Some hypotheses 
could be put forward. Some of them are given below. 
1. Increased levels of magnesium ions in the water supply of the 
study population: 
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The population of Tirunelveli district and the neighbouring districts in Tamil Nadu 
are relatively arid regions. The supply of drinking water is largely from the ground 
water. The ground water is obtained by means of bore wells. The water thus 
obtained is mainly hard water. Hard water contains increased levels of magnesium 
ions when compared to hard water. 
Hard water is water that has high mineral . Hard water is formed when 
water percolates through deposits of calcium and magnesium-containing minerals 
such as limestone, chalk and dolomite. Hard water is not a health hazard.  
Soft water contains 0-20 mg/L of MgCO3 while hard water may contain 
upto 60-180 mg/L of MgCO3. 
The mean magnesium levels of the control population are also higher than 
the mean levels of magnesium levels in the general population. This may be an 
evidence to support this hypothesis. 
2. Increased magnesium intake through diet. 
The richest sources of magnesium in diet are legumes, beans and green leafy 
vegetables. They contain about 500mg/ kilogram of magnesium. Indian diet, 
when compared to western diet is relatively richer in green leafy vegetables 
and legumes. Most of the studies were performed on western population. 
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This may account for the slightly increased mean magnesium levels in 
controls when compared to the general population. 
3. Genetic variability in the study population. 
The study population that mainly consisted of south Indians are 
constitutionally different from the Caucasians and black populations in 
which most of the western studies were conducted. In such a population 
group, the magnesium homeostasis may be different from western 
population. Although this is a remote possibility, we should keep this in the 
back of our minds, especially when we know the difference in clinical 
profile of acute MI patients of South Asia and the western population. 
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Summary 
 A total of 70 cases of Acute Myocardial infarction patients who 
presented to ICCU in Tirunelveli Medical College during the time period of 
August 2013 to September 2014 were studied for their magnesium levels at the 
time of presentation. Blood samples were collected within 6 hours of admission. 
They were monitored during their duration of admission for any complications. 
The study population was divided into three subgroups according to the age of the 
patients. 30 young healthy individuals were taken as the control group. 
 The magnesium levels were measured using colorimetric method 
with calmagite being the reagent used. 
 On analysis of the data, the prevalence of hypomagnesaemia in the 
study population was not significant. 
 The mean serum magnesium level of the study population was 
significantly lower than that of the control population. (2.009 mg/dl vs 2.177mg/dl) 
 There were also significantly low magnesium levels in two of the 
three subgroups, when compared to the controls. The age group from 45 to 55 had 
lower levels of mean magnesium levels, but it was not statistically significant.   
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Conclusion 
 The prevalence of hypomagnesemia in the study population was 
not significant. However the mean serum magnesium  levels in the study 
population as a whole was significantly lower than that of the control group. The 
reduction in magnesium levels were not statistically significant in one of the three 
subgroups whose age group was 45-55 years. 
 This is in concordance with previous studies on this topic. 
Magnesium levels do fall significantly in Acute myocardial infarction patients. 
However in this study the fall in magnesium is not high enough to cause 
hypomagnesemia and result in any increase in complications. 
 The probable cause for this result may be due to the high 
magnesium content of the drinking water (Hard Water) in the area in an around 
Tirunelveli district. More such studies are needed especially with a bigger sample 
size to find out if the current results are reproducible or not. 
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Proforma 
Case No: 
Name of the Patient: 
Age: 
Presenting Complaints: 
Past History(Diabetes, Hypertension,CAD): 
Drug History: 
Personal History (Smoking, Alcohol): 
General Examination: 
Vitals: 
Cardiovascular System: 
Other System Examination: 
ECG Findings: 
 
Serum Magnesium Levels: 
Follow up notes: 
 
 
CONSENT: I, the undersigned agree voluntarily to be included in the study. I 
Understand that this is a minimal invasive procedure.The procedure is explained to 
me in my own words. I agree to give 5ml of blood for the investigation. 
 
Date: 
Place:          Signature 
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Master Chart 
Total Cases [n=70] 
Numbe
r Name Age 
Serum 
Magnesium(mg/100ml) 
1 Muthuramalingam 44 2.6 
2 Subbiah 44 1.9 
3 Murugan 41 1.9 
4 Chelladurai 38 1.9 
5 
Mohammed 
Aboobakker 39 
1.9 
6 Murukan 38 1.2 
7 Paramasivam 30 1.8 
8 Jayatheswaram 40 2.1 
9 Sivaraman 37 1.9 
10 Appakkutty 35 1.8 
11 Chinnasamy 35 1.8 
12 Balakrishnan 28 2.1 
13 Velmurugan 32 2.1 
14 Shanmugam 30 3 
15 Peer Mohammed 39 2.1 
16 Shivadas 42 1.7 
17 Krishnakumar 44 2.2 
18 Arjun 44 2 
19 Michael 33 2.3 
20 Pandiraj 32 1.9 
21 Ramiah 39 1.8 
22 Arulraj 42 1.6 
23 Palavesem 54 2.2 
24 Vijayaraj 47 2.3 
25 John Kennedy 50 2.5 
26 Natchthiram 50 1.6 
27 Velu 53 1.8 
28 Suryanarayanan 46 2.6 
29 Arunachalam 50 1.7 
30 Pitchiah 52 1.8 
31 Ramalingam  51 2.1 
32 Selvaraj  54 2.1 
33 Ramasamy  50 2.3     
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34 Jayasankar 45 2.5 
35 Nadar Ali 45 1.9 
36 Selvan 45 1.9 
37 Abdul kathar 55 1.6 
38 Ramanujan 49 2.3 
39 Ayyadurai 53 1.9 
40 Velayuthan 47 2 
41 Jesudas 46 1.8 
42 Palamimurigan 54 1.6 
43 Venkatesh 50 2.4 
44 Muthukumar 54 2.1 
45 Shahjahan 46 1.7 
46 Periyasamy 51 2.2 
47 Muthu 56 1.6 
48 Palavesam 61 1.9 
49 Selvaraj 65 2 
50 Thalavai 75 1.8 
51 Victor 60 2.4 
52 Natarajan 65 2.2 
53 Shanmugavel 68 1.8 
54 Eswaran  60 1.9 
55 Moosha  57 1.9 
56 Ramasamy 68 1.8 
57 Ranganathan 61 1.6 
58 Samuel 75 2.2 
59 Mariappan 60 2.4 
60 Vallinayakam 75 2 
61 Manoharan 59 2.1 
62 Pandaram 65 1.8 
63 Esakkipandi 68 2 
64 Hyder Ali 58 2.4 
65 Ganeshan 57 1.7 
66 Esakkiappan 72 1.9 
67 Joseph 61 2.2 
68 Murukan 63 2.3 
69 Vishnudas 64 1.8 
70 Palaniappan 62 2.4 
  MEAN   2.01 
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Control [n=30] 
Number Name Age Serum Magnesium (mg/100ml) 
1 Benny 25 1.7 
2 Venkatesh Raju 28 2.2 
3 Raeez 26 2.3 
4 Alex Mathew 27 2.5 
5 Ayyadurai 66 1.5 
6 Kalimuthu 22 2.3 
7 Dileepan 23 2 
8 Gomathy 22 2.2 
9 Ankit 22 2.2 
10 Anu 24 2.3 
11 Kumar 30 2.3 
12 Saravanan 26 2.1 
13 Jered 27 2.1 
14 Sayee Venkatesh 27 2.8 
15 Arun Paulose 28 1.7 
16 Jose Paikkada 28 2.2 
17 Ibrahim Ali 34 2.4 
18 Prasanna 30 2.7 
19 Arun Kumar 27 1.9 
20 Balachander 27 2.2 
21 Balamarimuthu 24 1.8 
22 Sriram 23 2.4 
23 R Rajkumar 23 2.2 
24 Hariharan 23 1.7 
25 Krishna 22 1.9 
26 Balamurugan 24 2.2 
27 Chelladurai 55 2.6 
28 Gopal 40 2 
29 Vijay 26 2.3 
30 Jithin Raj 27 2.6 
  MEAN   2.18 
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Abbreviations 
CVD-  Cardiovascular disease 
CHD-Coronary Heart Disease 
IHD- Ischemic Heart Disease 
CVA- Cerebrovascular Accident 
MI – Myocardial Infarction 
STEMI – ST segment elevation Myocardial infarctiom 
NSTEMI- Non ST segment elevation Myocardial Infarction 
Mg 2+ -Magnesium ions. 
Ca2+  -Calcium ions. 
K+ -Potassium ions 
Na+ Sodium ions 
VT – Ventricular Tachycardia 
SVT- Supraventricular Ventricular Tachycardia 
AF – Atrial Fibrillation 
I.V – Intravenous 
A.T.P Adenosine Tri Phosphate 
cAMP –Cyclic Adenosine Monophosphate 
NADPH- Nicotinamide Adenide Diphosphate Hydrogen 
S.D – Standard Deviation. 
 
 
 
